Investment House LLC grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 46.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 65,135 shares of the company’s stock after buying an additional 20,725 shares during the quarter. Investment House LLC’s holdings in Zoetis were worth $4,153,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of the company. BlackRock Inc. raised its position in shares of Zoetis by 3.9% during the 2nd quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after buying an additional 1,412,829 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Zoetis by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock valued at $2,099,379,000 after buying an additional 910,265 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of Zoetis by 55.4% during the 2nd quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock valued at $646,905,000 after buying an additional 3,695,449 shares in the last quarter. Clearbridge Investments LLC raised its position in shares of Zoetis by 4.2% during the 1st quarter. Clearbridge Investments LLC now owns 9,254,662 shares of the company’s stock valued at $493,921,000 after buying an additional 373,568 shares in the last quarter. Finally, American Century Companies Inc. raised its position in shares of Zoetis by 7.2% during the 2nd quarter. American Century Companies Inc. now owns 6,207,974 shares of the company’s stock valued at $387,253,000 after buying an additional 417,455 shares in the last quarter. Hedge funds and other institutional investors own 93.04% of the company’s stock.
Zoetis Inc. (NYSE:ZTS) traded up 1.55% during trading on Wednesday, hitting $64.81. 992,470 shares of the company traded hands. The stock has a market capitalization of $31.70 billion, a PE ratio of 36.64 and a beta of 1.02. The company’s 50 day moving average is $64.45 and its 200-day moving average is $61.94. Zoetis Inc. has a 52 week low of $48.24 and a 52 week high of $66.35.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.53. The firm had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.49 earnings per share. Analysts predict that Zoetis Inc. will post $2.34 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Thursday, November 9th will be issued a $0.105 dividend. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date of this dividend is Wednesday, November 8th. Zoetis’s payout ratio is presently 23.73%.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/11/01/investment-house-llc-boosts-stake-in-zoetis-inc-zts.html.
Several research firms have recently weighed in on ZTS. Cowen and Company set a $70.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research report on Monday, July 17th. Cantor Fitzgerald set a $75.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research report on Monday, August 14th. BidaskClub cut shares of Zoetis from a “hold” rating to a “sell” rating in a research report on Wednesday. Stifel Nicolaus restated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research report on Friday, July 21st. Finally, Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $62.00 price objective on shares of Zoetis in a research report on Monday, August 7th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $65.76.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.